Tumor-stroma: Role of the tumor microenvironment during bone metastasis: Unveiling therapeutic targets

Drug Discovery Today: Disease Models

Volumn 8, Issue 2-3, 2011, Pages 87-93

  Lecanda, Fernando ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; INTEGRIN; MATRIX METALLOPROTEINASE INHIBITOR; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE METASTASIS; CANCER INVASION; CELL HOMING; CELL INTERACTION; CELL SURVIVAL; DRUG RESEARCH; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS INHIBITION; NONHUMAN; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 82455212879     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2011.07.010     Document Type: Review

References (65)

1. Roodman, G. D. (2004) Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664
2. Orimo, A. et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (Pubitemid 40692295)
3. Christopher, M. J. et al. (2009) Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokineinduced mobilization. Blood 114, 1331-1339
4. Muller, A. et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (Pubitemid 32225831)
5. Smith, M. C. et al. (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64, 8604-8612 (Pubitemid 39552073)
6. Sun, Y. X. et al. (2005) Skeletal localization and neutralization of the SDF- 1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 20, 318-329
7. Lapteva, N. et al. (2005) CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 12, 84-89 (Pubitemid 39665246)
8. Kopp, H. G. et al. (2009) Functional heterogeneity of the bone marrow vascular niche. Ann. N. Y. Acad. Sci. 1176, 47-54
9. Kang, Y. et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (Pubitemid 36808649)
10. Shiozawa, Y. et al. (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312
11. Mori, Y. et al. (2004) Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149-2154 (Pubitemid 39297870)
12. Zhao, Y. et al. (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 67, 5821-5830 (Pubitemid 46985016)
13. Bradley, D. A. et al. (2010) Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest. New Drugs
14. Khalili, P. et al. (2006) A non-RGD-based integrin binding peptide (ATN- 161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5, 2271-2280 (Pubitemid 44530464)
15. Brooks, P. C. et al. (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822
16. Harms, J. F. et al. (2004) A small molecule antagonist of the alpha (v) beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 21, 119-128 (Pubitemid 38988085)
17. Azab, A. K. et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351
18. Nervi, B. et al. (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206-6214
19. Yin, J. J. et al. (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. U. S. A. 100, 10954-10959 (Pubitemid 37140134)
20. Li, Z. G. et al. (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 118, 2697-2710
21. Guise, T. A. et al. (1996) Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98, 1544-1549 (Pubitemid 26327863)
22. Bendre, M. S. et al. (2005) Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 65, 11001-11009 (Pubitemid 41713370)
23. Coxon, F. P. et al. (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol. 6, 307-312 (Pubitemid 43670914)
24. Fizazi, K. et al. (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564-1571
25. Stopeck, A. T. et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139
26. Peyruchaud, O. et al. (2003) Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J. Biol. Chem. 278, 45826-45832 (Pubitemid 37432728)
27. Wilson, T. J. et al. (2009) Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1. Cancer Res. 69, 3188-3195
28. Le Gall, C. et al. (2007) A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67, 9894-9902 (Pubitemid 47621238)
29. Rucci, N. et al. (2008) Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med. Chem. 8, 342-349 (Pubitemid 351761438)
30. Yin, J. J. et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (Pubitemid 29053137)
31. Vicent, S. et al. (2008) A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res. 68, 2275-2285 (Pubitemid 351521801)
32. Kominsky, S. L. et al. (2007) TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. J. Bone Miner. Res. 22, 37-44 (Pubitemid 46032595)
33. Thomas, D. A. and Massague, J. (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380 (Pubitemid 41579832)
34. Kimura, T. et al. (2010) Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin. Cancer Res. 16, 121-129
35. Wang, N. et al. (2009) Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol. Ther. 17, 1241-1249
36. Friedl, P. and Wolf, K. (2008) Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res. 68, 7247-7249
37. Sabeh, F. et al. (2004) Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 167, 769-781 (Pubitemid 39565156)
38. Hernandez, I. et al. (2010) Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene 29, 3758-3769
39. Lynch, C. C. et al. (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7, 485-496 (Pubitemid 40719131)
40. Boire, A. et al. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (Pubitemid 40222426)
41. Lu, X. et al. (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 23, 1882-1894
42. Egeblad, M. and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174 (Pubitemid 37328786)
43. Coussens, L. M. et al. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (Pubitemid 34270240)
44. Huang, D. et al. (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053-1062
45. Dong, J. et al. (2004) VEGF-null cells require PDGFR alpha signalingmediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 23, 2800-2810 (Pubitemid 39013552)
46. Mathew, P. et al. (2009) Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J. Urol. 181, 81-87 (discussion 87)
47. Kim, S. J. et al. (2006) Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J. Natl. Cancer Inst. 98, 783-793
48. Catena, R. et al. (2011) PDGFR Signaling Blockade in Marrow Stroma Impairs Lung Cancer Bone Metastasis. Cancer Res. 71, 164-174
49. Sethi, N. and Kang, Y. (2011) Dysregulation of developmental pathways in bone metastasis. Bone 48, 16-22
50. Artavanis-Tsakonas, S. et al. (1999) Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (Pubitemid 29291335)
51. Kopan, R. and Ilagan, M. X. (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233
52. Sethi, N. et al. (2011) Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192-205
53. Rizzo, P. et al. (2008) Rational targeting of Notch signaling in cancer. Oncogene 27, 5124-5131
54. Yauch, R. L. et al. (2008) A paracrine requirement for Hedgehog signalling in cancer. Nature 455, 406-410
55. Das, S. et al. (2011) Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J. Biol. Chem. 286, 9612-9622
56. Sterling, J. A. et al. (2006) The Hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res. 66, 7548-7553 (Pubitemid 44289210)
57. Alexaki, V. I. et al. (2010) GLI2-mediated melanoma invasion and metastasis. J. Natl. Cancer Inst. 102, 1148-1159
58. Voorzanger-Rousselot, N. et al. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br. J. Cancer 97, 964-970 (Pubitemid 47519305)
59. Tian, E. et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494 (Pubitemid 38010074)
60. Oshima, T. et al. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106, 3160-3165 (Pubitemid 41565914)
61. Dai, J. et al. (2008) Prostate cancer induces bone metastasis through Wntinduced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 68, 5785-5794
62. Clines, G. A. et al. (2007) Dickkopf homolog 1 mediates endothelin-1- stimulated new bone formation. Mol. Endocrinol. 21, 486-498 (Pubitemid 46184897)
63. Nelson, J. B. et al. (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1, 944-949
64. Carducci, M. A. and Jimeno, A. (2006) Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin. Cancer Res. 12
65. Shepard, D. R. and Dreicer, R. (2010) Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opin. Investig. Drugs 19, 899-908